$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2011 Q4 Form 10-Q Financial Statement

#000106282211000062 Filed on November 01, 2011

Income Statement

Concept	2011 Q4	2011 Q3	2010 Q4
Revenue	$343.0K	$355.0K	$1.300M
YoY Change	-73.62%	-54.55%	-7.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.000M	$4.100M	$3.900M
YoY Change	2.56%	-16.33%	-11.36%
% of Gross Profit
Research & Development	$28.10M	$19.66M	$18.30M
YoY Change	53.55%	3.77%	-2.66%
% of Gross Profit
Depreciation & Amortization	$1.100M	$1.200M	$1.300M
YoY Change	-15.38%	-14.29%	-7.14%
% of Gross Profit
Operating Expenses	$33.70M	$26.05M	$23.70M
YoY Change	42.19%	4.04%	1.72%
Operating Profit	-$33.34M	-$25.69M
YoY Change		5.93%
Interest Expense	-$500.0K	$560.0K	-$600.0K
YoY Change	-16.67%	-12.09%	50.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$88.00K	$0.00
YoY Change		-103.26%	-100.0%
Pretax Income	-$33.80M	-$26.10M	-$23.00M
YoY Change	46.96%	-5.21%	0.88%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$33.85M	-$26.10M	-$23.00M
YoY Change	47.15%	-5.12%	4.55%
Net Earnings / Revenue	-9867.35%	-7352.96%	-1769.23%
Basic Earnings Per Share
Diluted Earnings Per Share	-$676.0K	-$541.5K	-$477.2K
COMMON SHARES
Basic Shares Outstanding	337.7M shares	337.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2011 Q4	2011 Q3	2010 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$281.3M	$143.7M	$211.1M
YoY Change	33.25%	-37.79%	29.91%
Cash & Equivalents	$186.3M	$30.52M	$47.21M
Short-Term Investments	$95.00M	$113.2M	$163.9M
Other Short-Term Assets	$3.748M	$4.337M	$2.883M
YoY Change	30.0%	31.42%	-54.95%
Inventory
Prepaid Expenses
Receivables	$350.0K	$489.0K	$744.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$285.8M	$149.0M	$214.7M
YoY Change	33.09%	-36.77%	26.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.42M	$47.34M	$53.43M
YoY Change	-13.12%	-14.54%	-9.14%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.1%
Intangibles	$53.56M	$53.56M	$53.56M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$205.0K	$281.0K	$619.0K
YoY Change	-66.88%	-43.8%	-82.31%
Total Long-Term Assets	$144.7M	$145.7M	$152.1M
YoY Change	-4.88%	7.71%	72.7%
TOTAL ASSETS
Total Short-Term Assets	$285.8M	$149.0M	$214.7M
Total Long-Term Assets	$144.7M	$145.7M	$152.1M
Total Assets	$430.5M	$294.7M	$366.9M
YoY Change	17.34%	-20.54%	42.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.042M	$5.526M	$3.159M
YoY Change	91.26%	53.5%	-46.46%
Accrued Expenses	$13.79M	$7.703M	$6.264M
YoY Change	120.08%	4.09%	11.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.443M	$1.413M	$1.138M
YoY Change	26.8%	28.45%	-97.04%
Total Short-Term Liabilities	$21.39M	$14.81M	$10.78M
YoY Change	98.52%	14.78%	-78.87%
LONG-TERM LIABILITIES
Long-Term Debt	$23.45M	$23.83M	$27.35M
YoY Change	-14.24%	-13.67%	-4.05%
Other Long-Term Liabilities	$55.15M	$53.64M	$48.78M
YoY Change	13.04%	-12.64%	229.61%
Total Long-Term Liabilities	$78.60M	$77.46M	$76.13M
YoY Change	3.24%	-12.96%	75.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.39M	$14.81M	$10.78M
Total Long-Term Liabilities	$78.60M	$77.46M	$76.13M
Total Liabilities	$132.9M	$125.2M	$119.9M
YoY Change	10.92%	22.77%	27.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$789.6M	-$755.8M	-$673.4M
YoY Change	17.26%
Common Stock	$480.0K	$338.0K	$338.0K
YoY Change	42.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$345.0K	$345.0K	$237.0K
YoY Change	45.57%
Treasury Stock Shares	218.0K shares	218.0K shares	158.0K shares
Shareholders Equity	$297.6M	$169.5M	$247.0M
YoY Change
Total Liabilities & Shareholders Equity	$430.5M	$294.7M	$366.9M
YoY Change	17.34%	-20.54%	42.31%

Cashflow Statement

Concept	2011 Q4	2011 Q3	2010 Q4
OPERATING ACTIVITIES
Net Income	-$33.85M	-$26.10M	-$23.00M
YoY Change	47.15%	-5.12%	4.55%
Depreciation, Depletion And Amortization	$1.100M	$1.200M	$1.300M
YoY Change	-15.38%	-14.29%	-7.14%
Cash From Operating Activities	-$22.50M	-$20.20M	-$19.40M
YoY Change	15.98%	8.02%	12.79%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$200.0K	-$200.0K
YoY Change	0.0%	-33.33%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$18.30M	$30.90M	-$144.8M
YoY Change	-112.64%	-6280.0%	-24233.33%
Cash From Investing Activities	$18.10M	$30.70M	-$145.1M
YoY Change	-112.47%	-3937.5%	-24283.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	160.3M	-400.0K	-200.0K
YoY Change	-80250.0%	-97.55%	-100.37%
NET CHANGE
Cash From Operating Activities	-22.50M	-20.20M	-19.40M
Cash From Investing Activities	18.10M	30.70M	-145.1M
Cash From Financing Activities	160.3M	-400.0K	-200.0K
Net Change In Cash	155.9M	10.10M	-164.7M
YoY Change	-194.66%	-128.21%	-534.56%
FREE CASH FLOW
Cash From Operating Activities	-$22.50M	-$20.20M	-$19.40M
Capital Expenditures	-$200.0K	-$200.0K	-$200.0K
Free Cash Flow	-$22.30M	-$20.00M	-$19.20M
YoY Change	16.15%	8.7%	12.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3159000	USD
CY2011Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5526000	USD
CY2010Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	744000	USD
CY2011Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	489000	USD
CY2010Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6264000	USD
CY2011Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7703000	USD
CY2011Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	79404000	USD
CY2010Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80323000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2011Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	34000	USD
CY2011Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	925230000	USD
CY2010Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	920324000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4354000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3958000	USD
CY2011Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2010Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2011Q3	us-gaap	Assets Assets	294706000	USD
CY2010Q4	us-gaap	Assets Assets	366884000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-96000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6328000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	214738000	USD
CY2011Q3	us-gaap	Assets Current AssetsCurrent	148981000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47208000	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30521000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100554000	USD
CY2010Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211988000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16687000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	111434000	USD
CY2010Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2011Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2011Q3	us-gaap	Common Stock Value CommonStockValue	338000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	338000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-78777000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-82341000	USD
	us-gaap	Contracts Revenue ContractsRevenue	1312000	USD
	us-gaap	Contracts Revenue ContractsRevenue	3437000	USD
CY2011Q3	us-gaap	Contracts Revenue ContractsRevenue	335000	USD
CY2010Q3	us-gaap	Contracts Revenue ContractsRevenue	632000	USD
CY2010Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	214000	USD
CY2011Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164000	USD
CY2010Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14212000	USD
CY2011Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14212000	USD
CY2011Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2010Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3752000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4082000	USD
CY2010Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2011Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	141000	USD
CY2010Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	94000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	USD
CY2010Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4948000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15535000	USD
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4055000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13340000	USD
CY2010Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2011Q3	us-gaap	Goodwill Goodwill	44543000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	50000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	800000	USD
	lxrx	Amortization Of Symphony Icon Inc Purchase Option AmortizationOfSymphonyIconIncPurchaseOption	3957000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26103000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	338000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-82370000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78802000	USD
CY2010Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27539000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26000	USD
CY2011Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2010Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3824000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3311000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	108000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-255000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	50000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	95000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1454000	USD
	us-gaap	Indefinite Lived Intangible Assets Acquired During Period IndefiniteLivedIntangibleAssetsAcquiredDuringPeriod	0	USD
	us-gaap	Indefinite Lived Intangible Assets Acquired During Period IndefiniteLivedIntangibleAssetsAcquiredDuringPeriod	-43557000	USD
CY2011Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2010Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2010Q3	us-gaap	Interest Expense InterestExpense	637000	USD
	us-gaap	Interest Expense InterestExpense	2093000	USD
	us-gaap	Interest Expense InterestExpense	1977000	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	560000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1925000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1828000	USD
CY2011Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	60000	USD
CY2010Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	51000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	468000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	215000	USD
CY2010Q4	us-gaap	Liabilities Liabilities	119860000	USD
CY2011Q3	us-gaap	Liabilities Liabilities	125225000	USD
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	366884000	USD
CY2011Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294706000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10775000	USD
CY2011Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14806000	USD
	us-gaap	Licenses Revenue LicensesRevenue	194000	USD
CY2011Q3	us-gaap	Licenses Revenue LicensesRevenue	20000	USD
CY2010Q3	us-gaap	Licenses Revenue LicensesRevenue	149000	USD
	us-gaap	Licenses Revenue LicensesRevenue	218000	USD
CY2010Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1138000	USD
CY2011Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1413000	USD
CY2010Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	27345000	USD
CY2011Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23826000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143132000	USD
CY2010Q3	us-gaap	Net Income Loss NetIncomeLoss	-27513000	USD
	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets	-1456000	USD
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	26046000	USD
CY2010Q3	us-gaap	Operating Expenses OperatingExpenses	25034000	USD
	us-gaap	Operating Expenses OperatingExpenses	76948000	USD
	us-gaap	Operating Expenses OperatingExpenses	82259000	USD
CY2010Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24253000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3163000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	51923000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	31257000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62955000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65447000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-78776000	USD
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	-26103000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-82370000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-73293000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-80753000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-25691000	USD
CY2011Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4337000	USD
CY2010Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2883000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	619000	USD
CY2011Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	281000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	29000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48783000	USD
CY2011Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	53636000	USD
CY2010Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2700000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	145000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4025000	USD
CY2011Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	88000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	108000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	149000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5561000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5999000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	82625000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	878000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	997000	USD
	lxrx	Amortization Of Symphony Icon Inc Purchase Option AmortizationOfSymphonyIconIncPurchaseOption	0	USD
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	-108000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	132923000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	44000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2622000	USD
	us-gaap	Profit Loss ProfitLoss	-82370000	USD
CY2011Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2011Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	189000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	181491000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11377000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	43651000	USD
	us-gaap	Profit Loss ProfitLoss	-78776000	USD
CY2011Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47344000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53427000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3244000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	49587000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60268000	USD
CY2011Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19655000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63721000	USD
CY2010Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18941000	USD
CY2011Q3	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2010Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2011Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-755776000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-673406000	USD
	us-gaap	Revenues Revenues	1506000	USD
	us-gaap	Revenues Revenues	3655000	USD
CY2011Q3	us-gaap	Revenues Revenues	355000	USD
CY2010Q3	us-gaap	Revenues Revenues	781000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4354000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3958000	USD
CY2011Q3	us-gaap	Short Term Investments ShortTermInvestments	113634000	USD
CY2010Q4	us-gaap	Short Term Investments ShortTermInvestments	163903000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	181474000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	363000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	189000	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	169481000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	247024000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	-149000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	29000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1000	USD
CY2009Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	163497000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	247024000	USD
CY2011Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	169481000	USD
CY2010Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	268854000	USD
CY2011Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	218000	shares
CY2010Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	158000	shares
CY2011Q3	us-gaap	Treasury Stock Value TreasuryStockValue	345000	USD
CY2010Q4	us-gaap	Treasury Stock Value TreasuryStockValue	237000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	5198000	USD
CY2011Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2336000	USD
CY2010Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1145000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1145000	USD
	lxrx	Deconsolidation Of Symphony Icon Inc DeconsolidationOfSymphonyIconInc	290000	USD
CY2010Q3	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	337404000	shares
CY2011Q3	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	337678000	shares
	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	291196000	shares
	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	337625000	shares
CY2010Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	582000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1874000	USD
CY2011Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	609000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1592000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2480000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2366000	USD
CY2011Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	823000	USD
CY2010Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	751000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
	dei	Document Period End Date DocumentPeriodEndDate	2011-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2011Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	337677864	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-11-000062-index-headers.html	Edgar Link	pending
0001062822-11-000062-index.html	Edgar Link	pending
0001062822-11-000062.txt	Edgar Link	pending
0001062822-11-000062-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
lxrx-20110930.xml	Edgar Link	completed
lxrx-20110930.xsd	Edgar Link	pending
lxrx-20110930_cal.xml	Edgar Link	unprocessable
lxrx-20110930_def.xml	Edgar Link	unprocessable
lxrx-20110930_lab.xml	Edgar Link	unprocessable
lxrx-20110930_pre.xml	Edgar Link	unprocessable
lxrx930201110-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2011 Q4 Form 10-Q Financial Statement

#000106282211000062 Filed on November 01, 2011

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2011 Q4 Form 10-Q Financial Statement

#000106282211000062 Filed on November 01, 2011

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx